Other analysts have also issued research reports about the company. Cantor Fitzgerald reissued a neutral rating and issued a $1.30 target price on shares of Oncternal Therapeutics in a research report on Thursday, September 7th. HC Wainwright upgraded shares of Oncternal Therapeutics from a neutral rating to a buy rating and set a $2.00 price target for the company in a research note on Monday, September 18th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Oncternal Therapeutics has an average rating of Hold and a consensus target price of $4.10.
Oncternal Therapeutics Stock Down 3.3 %
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last announced its earnings results on Thursday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.17 million. Oncternal Therapeutics had a negative net margin of 4,985.85% and a negative return on equity of 75.67%. Analysts anticipate that Oncternal Therapeutics will post -0.64 EPS for the current fiscal year.
Hedge Funds Weigh In On Oncternal Therapeutics
Large investors have recently bought and sold shares of the stock. Richmond Brothers Inc. acquired a new position in Oncternal Therapeutics in the first quarter valued at $30,000. Two Sigma Advisers LP boosted its stake in Oncternal Therapeutics by 118.5% in the third quarter. Two Sigma Advisers LP now owns 295,200 shares of the company’s stock valued at $263,000 after acquiring an additional 160,100 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Oncternal Therapeutics by 13.0% in the second quarter. Goldman Sachs Group Inc. now owns 189,634 shares of the company’s stock valued at $211,000 after acquiring an additional 21,785 shares in the last quarter. UBS Group AG boosted its stake in Oncternal Therapeutics by 1,373.8% in the second quarter. UBS Group AG now owns 166,298 shares of the company’s stock valued at $184,000 after acquiring an additional 155,014 shares in the last quarter. Finally, CI Private Wealth LLC acquired a new position in Oncternal Therapeutics in the fourth quarter valued at $150,000. Institutional investors and hedge funds own 16.05% of the company’s stock.
Oncternal Therapeutics Company Profile
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
- Five stocks we like better than Oncternal Therapeutics
- 3 Monster Growth Stocks to Buy Now
- Data giants MongoDB and Snowflake just got upgraded
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Plug Power at tipping point; it’s make or break time for hydrogen
- What Makes a Stock a Good Dividend Stock?
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.